Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Ms Marie-Christine Alessi
Clinical guidelines have recommended that individuals with risk factors for coronary heart disease should take aspirin for primary and secondary prevention. However subgroups analyses did not demonstrate any significant effect on reducing vascular events in patients suffering diabetes. More recently, two large primary prospectively designed prevention trials confimed these findings (JPAD, JAMA 2008 and POPADAD , Brit Med J 2008). These data question the causes of the clinical and biological non responsivness to aspirin in diabetics. Several hypotheses were put forward by Professor Patrono (Roma, It) to explain aspirin resistance in diabetic patients : glycation of COX1, rendering COX1 more effective, increased COX2 expression bypassing COX 1 and lastly a faster recovery of COX 1 activity in diabetic patients, reducing aspirin efficiency. This last hypothesis was nicely documented. Some heterogeneity in COX1 recovery has been observed suggesting that enhanced platelet turnover in a fraction of type 2 diabetes may allow sufficient recovery of COX1 activity and may blunt the aspirin effect.
Similarly to aspirin resistance, clopidogrel non responsivness is more frequently observed in diabetics. To overcome this difficulty, DJ angiolillo (Jacksonville, US) nicely described recent data showing the advantages of increasing clopidogrel doses, the benefit of combining clopidogrel with cilostazol or picotamide and the promise of new antiplatelet drugs.
In association to strict metabolic control, it is probable that ongoing trials focusing on the use of antiplatelet agents in diabetics will help to explore alternative regimens of antiplatelet therapy and to identify patients that may benefit from tailored antiplatelet treatment.
The diabetic platelet - an unsolved problem
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved